Comparison of Brain Natriuretic Peptide Levels to Simultaneously Obtained Right Heart Hemodynamics in Stable Outpatients with Pulmonary Arterial Hypertension

Pulmonary arterial hypertension (PAH) is a progressive disease that requires validated biomarkers of disease severity. While PAH is defined hemodynamically by right heart catheterization (RHC), brain natriuretic peptide (BNP) is recommended by guidelines to assess disease status. Retrospectively col...

Full description

Saved in:
Bibliographic Details
Published inDiseases Vol. 6; no. 2; p. 33
Main Authors Helgeson, Scott A, Imam, J Saadi, Moss, John E, Hodge, David O, Burger, Charles D
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 01.05.2018
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Pulmonary arterial hypertension (PAH) is a progressive disease that requires validated biomarkers of disease severity. While PAH is defined hemodynamically by right heart catheterization (RHC), brain natriuretic peptide (BNP) is recommended by guidelines to assess disease status. Retrospectively collected data in 138 group 1 PAH patients were examined for the correlation of BNP levels to simultaneously obtained right heart catheterization (RHC). Patients were mostly Caucasian women, with functional class III symptoms, mean BNP of 406 ± 443 pg/mL, and an average right atrial pressure (RAP) of 9.9 ± 5.7 mm Hg and mean pulmonary artery pressure (mPAP) of 47.3 ± 14.7 mm Hg. Significant correlation was demonstrated between BNP and RAP ( = 0.021) and mPAP ( = 0.003). Additional correlation was seen with right heart size on echocardiography: right atrial (RAE; = 0.04) and right ventricular enlargement ( = 0.03). An increased BNP level was an independent predictor of mortality ( < 0.0001), along with RAP ( = 0.039) and RAE ( = 0.018). Simultaneous collection of BNP at the time of RHC confirmed the correlation of BNP with right heart hemodynamics. The current results reinforce the use of BNP level as a continuous variable to assess disease severity in group 1 PAH.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2079-9721
2079-9721
DOI:10.3390/diseases6020033